ANALYTICAL METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC METHOD FOR THE ESTIMATION OF UPADACITINIB BULK AND DOSAGE FORM
International Journal of Drug Delivery Technology · 14.07.2026 · 16 (64s)
DOI: 10.25258/ijddt.16.64s.71 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 14.07.2026. Verfasst von Dipali Nagesh Gabure und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Upadacitinib is a selective JAK1 inhibitor approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and inflammatory bowel disease. It works by blocking the JAK-STAT signaling pathway, suppressing cytokinedriven inflammation. Despite its growing clinical use, published RP-HPLC methods for routine quality control of upadacitinib in tablet dosage forms remain limited. Accurate quantification in bulk and formulated products is essential for regulatory compliance under ICH, WHO, and FDA guidelines.
Objectives
To develop a simple, sensitive, accurate, and economical RP-HPLC method for the estimation of upadacitinib in bulk drug substance and tablet dosage form (UPADOZ 30 mg), and to validate it according to ICH Q2(R1) guidelines. Materials and Methods: Upadacitinib bulk API (Vidisha Analytical) and UPADOZ 30 mg tablets (MSN Laboratories) were used. Chromatographic separation was performed on an Agilent 1260 Infinity II HPLC system using a Zorbax RX C18 column (150 × 4.6 mm, 5 µm). The mobile phase was Water: Acetonitrile (40:60 v/v), delivered at 1.0 mL/min with UV detection at 232 nm. Column temperature was maintained at 40°C and injection volume was 20 µL. Drug identity was confirmed by FTIR and UV spectroscopy prior to chromatographic analysis. Method validation covered system suitability, specificity, linearity, accuracy, precision (method and intermediate), and robustness per ICH guidelines.
Results
The method yielded a retention time of 3.37 minutes with a tailing factor of 1.40 and theoretical plates of 5635, all within acceptance criteria. Linearity was established from 30 to 90 ppm (r² = 1.000). Accuracy at 50%, 100%, and 150% levels gave mean recoveries of 100.22%, 100.36%, and 99.70%, respectively. Method precision showed %RSD of 0.415%, and intermediate precision %RSD was 0.5%. Blank and placebo showed no interference at the upadacitinib retention time. Robustness studies with deliberate changes in flow rate (±0.1 mL/min) and wavelength (±2 nm) met all system suitability criteria.
Conclusion
The developed RP-HPLC method is accurate, precise, specific, reproducible, and robust for routine estimation of upadacitinib in bulk and tablet formulation. It meets ICH validation requirements and can be reliably applied in pharmaceutical quality control laboratories.
Zitieren
APA
Gabure, D. N., Veer, V., & Bhosale, A. (2026). ANALYTICAL METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC METHOD FOR THE ESTIMATION OF UPADACITINIB BULK AND DOSAGE FORM. International Journal of Drug Delivery Technology, 16(64s). https://doi.org/10.25258/ijddt.16.64s.71
Vancouver
Gabure DN, Veer V, Bhosale A. ANALYTICAL METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC METHOD FOR THE ESTIMATION OF UPADACITINIB BULK AND DOSAGE FORM. International Journal of Drug Delivery Technology. 2026;16(64s). doi:10.25258/ijddt.16.64s.71
BibTeX
@article{Gabure2026,
author = {Gabure, Dipali Nagesh and Veer, Vikram and Bhosale, Ashok},
title = {ANALYTICAL METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC METHOD FOR THE ESTIMATION OF UPADACITINIB BULK AND DOSAGE FORM},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {64s},
doi = {10.25258/ijddt.16.64s.71}
}
EUVIMED